Retour sur lavenir.net
   AGFA-GEVAERT 0.420 € (-1,52 %)     UCB 252.400 € (+0,96 %)     BANQUP GROUP 1.880 € (+10,59 %)     KBC ANCORA 82.600 € (+2,48 %)     AZELIS GROUP 10.030 € (-1,28 %)     UMICORE 23.940 € (-0,25 %)     SOFINA 223.200 € (+1,64 %)     JENSEN-GROUP 83.600 € (-0,48 %)     SIPEF 92.900 € (-0,11 %)     TUBIZE-FIN 221.000 € (+1,56 %)     BPOST 1.642 € (-1,79 %)     VIOHALCO 19.300 € (+0,21 %)     FLUXYS BELGIUM D 19.850 € (+1,28 %)     RECTICEL 10.600 € (-1,12 %)     ONWARD MEDICAL 2.670 € (+1,52 %)     XIOR 26.000 € (-0,57 %)     RETAIL ESTATES 69.500 € (0,00 %)     CENERGY 23.740 € (-3,02 %)     ENERGYVISION 14.720 € (-0,27 %)     BREDERODE 103.200 € (-0,58 %)     CARE PROPERTY INV. 12.380 € (-0,48 %)     IMMOBEL 23.000 € (+5,99 %)     PROXIMUS 6.260 € (-1,96 %)     GBL 78.900 € (-0,44 %)     AGEAS 67.750 € (+0,44 %)     HYBRID SOFTWARE GR 4.000 € (+0,50 %)     GIMV 45.050 € (-0,11 %)     KBC 119.850 € (+1,78 %)     WDP 21.760 € (-1,09 %)     D'IETEREN GROUP 167.400 € (-0,36 %)     CAMPINE 229.000 € (+0,44 %)     WERELDHAVE BELGIUM 52.400 € (+0,38 %)     BEKAERT 42.500 € (+0,12 %)     TITAN S.A. 53.500 € (+1,23 %)     SOLVAY 27.640 € (+1,25 %)     ELIA GROUP 133.600 € (-0,22 %)     BARCO 8.645 € (+0,58 %)     EVS 29.800 € (0,00 %)     DECEUNINCK 2.330 € (+0,65 %)     VASTNED 29.500 € (-0,17 %)     QUESTFOR GR-PRICAF 2.974 € (-1,51 %)     TINC 11.700 € (-0,34 %)     COFINIMMO 81.150 € (-0,55 %)     SYENSQO 68.800 € (+1,25 %)     ACKERMANS V.HAAREN 287.200 € (+0,77 %)     SHURGARD 23.950 € (-0,83 %)     COLRUYT 35.000 € (+1,86 %)     IBA 16.720 € (+4,24 %)     TESSENDERLO 20.600 € (+1,48 %)     ONTEX GROUP 2.420 € (-2,42 %)     DEME GROUP 184.800 € (-0,22 %)     KINEPOLIS GROUP 35.300 € (-0,70 %)     AB INBEV 70.600 € (-0,81 %)     AEDIFICA 69.050 € (-0,29 %)     VAN DE VELDE 30.400 € (+0,33 %)     CIE BOIS SAUVAGE 306.000 € (0,00 %)     NYXOAH 1.468 € (+5,01 %)     ASCENCIO 51.700 € (-2,08 %)     HOME INVEST BE. 19.480 € (-0,61 %)     CFE 12.800 € (+2,40 %)  
   TOTALENERGIES 72.210 € (-1,15 %)     SOITEC 124.700 € (-3,07 %)     KERING 264.900 € (-0,17 %)     ROBERTET 812.000 € (-1,46 %)     SHELL PLC 35.110 € (-1,10 %)     AEGON 7.468 € (-0,27 %)     ENGIE 26.960 € (+0,22 %)     BASIC-FIT 31.800 € (-0,81 %)     EIFFAGE 130.250 € (+0,70 %)     AYVENS 11.900 € (-1,41 %)     EUTELSAT COMMUNIC. 2.554 € (-1,39 %)     WOLTERS KLUWER 59.800 € (-0,23 %)     LEGRAND 145.000 € (+4,54 %)     FLOW TRADERS 25.940 € (+0,39 %)     ABIVAX 88.300 € (+5,69 %)     ESSILORLUXOTTICA 174.750 € (-4,79 %)     ATOS 36.400 € (-0,66 %)     ASML HOLDING 1 656.400 € (+4,10 %)     BOIRON 27.500 € (-0,72 %)     AXA 42.530 € (+0,43 %)     ADYEN 888.300 € (-0,22 %)     THX PHARMA 3.720 € (-5,58 %)     AKZO NOBEL 59.000 € (+0,68 %)     GETLINK SE 18.570 € (+0,05 %)     VINCI 130.300 € (+0,85 %)     UMG 18.630 € (+2,93 %)     FUGRO 11.350 € (+2,44 %)     APERAM 48.980 € (-2,33 %)     SMCP 5.145 € (-0,19 %)     NEXITY 7.800 € (+0,71 %)     SAFRAN 324.000 € (0,00 %)     PERNOD RICARD 62.520 € (-1,39 %)     MEDINCELL 24.640 € (-12,06 %)     MICHELIN 33.320 € (-1,24 %)     TIKEHAU CAPITAL 17.640 € (-1,89 %)     SANOFI 74.880 € (-1,03 %)     2CRSI 44.600 € (-2,58 %)     STMICROELECTRONICS 65.160 € (-0,79 %)     CBI 0.109 € (+6,86 %)     RELX 28.360 € (+0,93 %)     S.E.B. 53.100 € (-2,75 %)     LVMH 511.000 € (-1,79 %)     DASSAULT SYSTEMES 17.315 € (-0,29 %)     ASM INTERNATIONAL 1 046.000 € (+5,89 %)     GL EVENTS 32.950 € (-0,90 %)     AMG 36.700 € (+2,86 %)     CHRISTIAN DIOR 474.400 € (-1,33 %)     GECINA 73.500 € (-1,01 %)     X-FAB 9.580 € (-2,15 %)     AHOLD DEL 35.390 € (-2,26 %)     AIRBUS 187.020 € (+0,93 %)     STELLANTIS NV 5.781 € (-3,21 %)     MEDIANTECHNOLOGIES 5.240 € (+2,75 %)     ACCOR 48.150 € (-0,72 %)     PLUXEE 11.380 € (+1,34 %)     CROSSJECT 1.896 € (-0,11 %)     ALTAREA 96.800 € (+0,31 %)     L'OREAL 382.150 € (-1,04 %)     INPOST 15.310 € (-0,07 %)     LHYFE 2.000 € (-0,99 %)  
News Réglementées
09/01/2023 20:00

The Power Play by The Market Herald Releases a New Interview with Algernon Pharmaceuticals Discussing Their Latest News

VANCOUVER, BC / ACCESSWIRE / January 9, 2023 / The Power Play by The Market Herald has announced the release of a new interview with Algernon Pharmaceuticals discussing their latest news.

The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know about the company's latest press release through exclusive insights and interviews with company executives.

Algernon Pharmaceuticals (CSE:AGN) announces upcoming phase 2b chronic cough study of Ifenprodil
The Market Herald, Monday, January 9, 2023, Press release picture

Algernon Pharmaceuticals (AGN) has announced plans for a 180-patient, 90-day Phase 2b clinical study of NP-120 for chronic cough in Q3 of 2023. Following discussions with the U.S. FDA, the company plans to file an investigational new drug (IND) application shortly. Christopher J. Moreau, CEO of Algernon Pharmaceuticals, sat down with Sabrina Cuthbert to discuss the upcoming study.

For the full interview with Christopher J. Moreau and to learn about Algernon Pharmaceuticals, click here.

Interviews for The Power Play by The Market Herald are released daily. To learn more about the companies featured in The Power Play or to explore our other interviews visit The Power Play by The Market Herald.

About The Market Herald

The Market Herald Canada is the leading source of authoritative breaking stock market news for self-directed investors. Our team of Canadian markets reporters, editors and technologists covers the entire listed company universe in Canada. We cover over 3,985 businesses, their people, their investors, and their customers. We write the stories that move the Canadian capital markets.

DISCLAIMER: Report Card Canada Media Ltd. ("Report Card") is a wholly-owned subsidiary of Market Herald Limited, an Australian company ("Market Herald"). Report Card is not an advisory service, and does not offer, buy, sell, or provide any other rating, analysis or opinion on the securities we discuss. We are retained and compensated by the companies that we provide information on to assist them with making information available to the public. All information available on themarketherald.ca and/or this press release should be considered as commercial advertisement and not an endorsement, offer or recommendation to buy or sell securities. Report Card is not registered with any financial or securities regulatory authority in any province or territory of Canada, will not be performing any registerable activity as defined by the applicable regulatory bodies and do not provide nor claim to provide investment advice or recommendations to any visitor of this site or readers of any content on or originating from themarketherald.ca. Market Herald and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Market Herald's affiliates. In such instances, Market Herald and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Market Herald and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize any conflict. All the information on this document and/or the website - themarketherald.ca - is published in good faith and for general information purpose only. Report Card does not make any warranties about the completeness, reliability, and accuracy of this information. Any action you take upon the information you find on this document and/or website (themarketherald.ca) is strictly at your own risk. Report Card will not be liable for any losses and/or damages in connection with the use of our website. From our website, you can visit other websites by following hyperlinks to such external sites. While we strive to provide only quality links to useful and ethical websites, we have no control over the content and nature of these sites. These links to other websites do not imply a recommendation for all the content found on these sites. Site owners and content may change without notice and may occur before we have the opportunity to remove a link which may have gone 'bad'. Please be also aware that when you leave our website, other sites may have different privacy policies and terms which are beyond our control. Please be sure to check the Privacy Policies of these sites as well as their "Terms of Service" before engaging in any business or uploading any information.

CONTACT:
The Market Herald
marketing@themarketherald.ca
themarketherald.ca

SOURCE: The Market Herald



View source version on accesswire.com:
https://www.accesswire.com/734527/The-Power-Play-by-The-Market-Herald-Releases-a-New-Interview-with-Algernon-Pharmaceuticals-Discussing-Their-Latest-News

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière